source
- Lilly expands access to its experimental obesity therapy while Jazz pulls Zepzelca's second-line lung cancer useLilly announced it will broaden the expanded‑access program for its obesity drug that has not yet received regulatory approval, allowing more patients to receive the treatment under a compassionate…
- FDA invites stakeholder input to shape a new Quantitative Medicine Innovation NetworkThe FDA announced it is looking for feedback from a broad range of stakeholders to help design a Quantitative Medicine Innovation Network (QMIN). The proposed QMIN would be a cross-sector platform…